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Abstract 
The polyphenol fraction of extra-virgin olive oil may be partly responsible for its cardioprotective 
effects. The aim of this systematic review and meta-analysis was to evaluate the effect of high versus 
low polyphenol olive oil on cardiovascular disease (CVD) risk factors in clinical trials. In accordance 
with PRISMA guidelines, CINAHL, PubMed, Embase and Cochrane databases were systematically 
searched for relevant studies. Randomized controlled trials that investigated markers of CVD risk 
(e.g. outcomes related to cholesterol, inflammation, oxidative stress) were included. Risk of bias was 
assessed using the Jadad scale. A meta-analysis was conducted using clinical trial data with available 
CVD risk outcomes. Twenty-six studies were included. Compared to low polyphenol olive oil, high 
polyphenol olive oil significantly improved measures of malondialdehyde (MD: -0.07µmol/L [95%CI: -
0.12, -0.02µmol/L]; I2: 88%; p=0.004), oxidized LDL (SMD: -0.44 [95%CI: -0.78, -0.10µmol/L]; I2: 41%; 
P=0.01), total cholesterol (MD 4.5mg/dL [95%CI: -6.54, -2.39mg/dL]; p<0.0001) and HDL cholesterol 
(MD 2.37mg/dL [95%CI: 0.41, 5.04mg/dL]; p=0.02). Subgroup analyses and individual studies 
reported additional improvements in inflammatory markers and blood pressure. Most studies were 
rated as having low-to-moderate risk of bias. High polyphenol oils confer some CVD-risk reduction 
benefits; however, further studies with longer duration and in non-Mediterranean populations are 
required. 
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Introduction 
Numerous epidemiological studies and landmark clinical trials suggest that the traditional 
Mediterranean diet is cardioprotective (de Lorgeril et al. 1999, Estruch et al. 2006, Itsiopoulos et al. 
2011, Itsiopoulos et al. 2011). There are many components of this dietary pattern that provide 
cardioprotective effects and mediate health benefits including red wine, high vegetable and fish 
intake, and the high consumption of extra virgin olive oil (EVOO). Clinical and animal studies 
demonstrate that EVOO can improve cardiovascular disease (CVD) outcomes including blood 
pressure, inflammation, and cholesterol levels (Perona et al. 2004, Beauchamp et al. 2005, Farras et 
al. 2015). 
EVOO is high in monounsaturated fatty acids (MUFAs) which may mediate the prevention and 
management of CVD and associated risk factors through various mechanisms including the favorable 
modulation of cholesterol levels and improvement of insulin sensitivity (Schwingshackl and 
Hoffmann 2012). In addition to the high MUFA content, the polyphenol content of EVOO may also 
be cardioprotective (Covas, Konstantinidou and Fito 2009). Studies that have directly compared olive 
 
 
 
 
 
 
 
oil with other high-MUFA oils, including flaxseed and sunflower oil, have shown superior outcomes 
in  low-density lipoprotein (LDL) oxidation, lipoprotein concentration, and LDL particle size with 
provision of olive oil (Aguilera et al. 2004, Harper, Edwards and Jacobson 2006). A systematic review 
and meta-analysis demonstrated that compared with seed oils, olive oil significantly improved total, 
high-density lipoprotein (HDL) (Ghobadi et al. 2018). Emerging preclinical and observational 
evidence suggests that dietary polyphenol intake may reduce inflammation and is associated with 
improved all-cause mortality (Tresserra-Rimbau et al. 2014, Joseph, Edirisinghe and Burton-Freeman 
2016). EVOO, compared to other dietary fats,(Perez-Jimenez et al. 2010) contains a unique 
composition of polyphenols. In particular, EVOO contains a high concentration of the polyphenols 
hydroxytyrosol and oleuropein, which in preclinical studies, have demonstrated cardioprotective 
properties including the favorable modulation of pathways related to inflammation, oxidative stress, 
homocysteine, cholesterol levels and cell adhesion (Parkinson and Cicerale 2016, Peyrol, Riva and 
Amiot 2017). 
To determine the relative contribution of olive oil polyphenols to the known beneficial properties of 
the fatty acid profile present in olive oil, numerous trials have investigated the effect of high 
polyphenol olive oil (HPOO) versus low polyphenol olive oil (LPOO). The aim of this systematic 
review and meta-analysis was to examine the evidence for modulation of cardiovascular risk factors 
in existing clinical trials that have compared the effect of HPOO versus LPOO. We examined whether 
polyphenols, specifically, elicited superior health outcomes and if the evidence supports 
recommendations for the preferential use of EVOO over refined olive oil. 
 
 
 
 
 
 
 
 Methods 
Literature search 
In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (Liberati et al. 2009) and as registered on PROSPERO (42017070060), relevant 
studies were retrieved from PubMed, Embase, The Cochrane Library, and CINAHL for articles 
published since journal inception up to June 2017. Search terms related to polyphenols (e.g. 
polyphenol, phenol, phytochemical) and olive oil were used.  
Studies were required to meet each of the following eligibility criteria to be included in this review: 
used a randomized or non-randomized, parallel or cross-over trial study design; investigated olive oil 
as a stand-alone intervention; conducted in adult participants (healthy or otherwise); compared 
higher polyphenol olive oil to an olive oil with a lower polyphenol content; and included markers of 
CVD (including lipids, hemodynamic, and inflammatory measures) and/or oxidative stress outcomes.  
 
 
Data extraction 
Screening of the title and abstracts for individual studies was conducted in duplicate by three 
authors (GLT, AJR or ACL) with disagreements resolved by consensus or fourth reviewer (WM). 
Articles deemed eligible for full-text review were assessed for eligibility independently by two 
authors (GLT, ACL) and agreement reached via group consensus (ESG, HM, GLT, WM). The following 
parameters were extracted from included studies: author/date, study design, sample size, total 
study period, population characteristics (including age, gender, and co-morbidities), intervention 
 
 
 
 
 
 
 
characteristics (including polyphenol content and duration of exposure), length of follow up and 
cardiovascular outcomes including lipids, hemodynamic, inflammatory measures, weight measures, 
endothelial function, and/or oxidative stress outcomes.  
If two manuscripts reported on the same outcomes using the same or a sub-sample of a participant 
cohort, data were only extracted for the manuscript that included the largest sample size. If the 
larger study reported outcomes with insufficient detail to be included in meta-analyses, outcomes 
from the smaller study were extracted and both were reported qualitatively. Data for study arms 
that did not meet the eligibility criteria of this review were not extracted. 
 
 
Assessment of study risk of bias 
Risk of bias was assessed independently by three authors (ESG, AF, ACT) using the Jadad scale (Jadad 
et al. 1996). The Jadad scale is a five-item scale that assesses risk of bias due to randomization, 
blinding, and follow up. Studies can receive a score between zero and five, with lower scores 
indicating a higher risk of bias. Conflicting scores were resolved collaboratively and if disagreements 
persisted, a fourth author (WM) made the final judgment. If two or more manuscripts reported on 
the same cohort (or sub-cohort), details regarding blinding and randomization were extracted from 
all manuscripts to assess bias.   
Data analysis  
For qualitative analysis, difference in end intervention measures between groups and change 
between groups were reported, depending on the analysis reported for individual studies. Data were 
considered statistically significant if the reported p-value was <0.05.  
 
 
 
 
 
 
 
When outcomes of included studies were sufficiently reported, data were pooled using Review 
Manager (Version 5.3, The Cochrane Collaboration 2014). Only outcomes relating to HPOO and 
LPOO were considered for comparison. To calculate the overall treatment effect, the difference 
between the outcomes at follow up of the intervention and comparison groups were considered. 
Continuous outcome variables were calculated using the inverse variance test as mean differences 
(MD) for studies which used the same measurement, or standardized mean differences (SMD) for 
studies which used different measures for the same construct; where SMD effect sizes of <0.4 were 
considered small, 0.4–0.7 moderate, and >0.7 large (Higgins, Julian and Green 2011). However, 
where biochemistry variables were reported via different units (e.g. mmol/L versus mg/dL); the 
measures were converted to the same unit and a MD was calculated. No categorical variables were 
pooled. 
To assist clinical interpretation, SMD effect sizes were transformed into the scale of one the clinical 
measures and presented as a product of the total baseline standard deviation of a measure (Higgins, 
Julian and Green 2011). Due to the complex nature of interpreting a single variable upon nutrition-
related health measures, a random effects model was used for all meta-analyses. An I2 statistic of 
>50% was considered substantially heterogeneous. Sensitivity analysis was applied with pooled 
effect sizes with substantial heterogeneity and/or a non-significant trend towards an effect. For 
outcomes related to lipid profile and hemodynamics, subgroup analyses were undertaken for 
healthy patients versus those with hyperlipidemia or hypertension, respectively. Meta-analyses with 
significant results are presented as a figure within the manuscript and meta-analyses with non-
significant results are included as supplementary material. 
 
 
 
 
 
 
 
Results 
Study selection 
The literature search identified 4241 citations after the removal of duplicates (Figure 1). Forty 
articles were retrieved for full text screening and after a further 14 studies were excluded, 26 articles 
were included for this review and meta-analysis.  
Study Characteristics 
The majority of the included manuscripts (15/26) reported on outcomes from two separate cohorts: 
the Effect of Olive Oil on Oxidative Damage in European Populations study (abbreviated as 
EUROLIVE; 8/26 studies), and the Virgin Olive Oil and HDL Functionality study (VOHF; 6/26 studies). 
The EUROLIVE study was a multi-center randomized, double-blind, controlled, cross-over trial in 200 
healthy males. Three of the 8 EUROLIVE studies reported on the full cohort while 5 studies reported 
on a subset. The VOHF study was a double-blind, randomized, controlled, crossover clinical trial of 
33 hyper-cholesterolemic adults. Four of the 6 VOHF studies reported on the full cohort, while 2 
studies reported on a subset. Perona et al. 2011 reported new outcomes using predominately the 
same cohort that was reported on in the study by Marrugat et al. 2004. Likewise, the paper by Fito 
et al.2008 reported outcomes using a sub-set of patients from Fito et al. 2005. The remaining 8 
studies reported on separate cohorts (see Table 1). 
Overall, the sample size of the included studies was relatively small; most studies included 10 to 49 
participants, with the exception of the EUROLIVE cohort, which included 200 participants. Twelve 
studies recruited healthy adult participants while the remaining studies recruited specific 
populations (such as smokers (Moschandreas et al. 2002) and post-menopausal women (Salvini et al. 
2006)) or participants with dyslipidemia, high blood pressure, fibromyalgia, and peripheral vascular 
disease (Ramirez-Tortosa et al. 1999, Fito et al. 2005, Visioli et al. 2005, Fito et al. 2008, Moreno-
Luna et al. 2012, Rus et al. 2016). 
 
 
 
 
 
 
 
Studies included participants recruited from either a combination of European countries (Spain, 
Denmark, Finland, Italy, Germany; 8/26 studies) or the following individual countries: Spain (13/26 
studies), Italy (2/26 studies), Netherlands (1/26 study), Greece (1/26 study), and Jordan (1/26 study).  
 
Trial intervention duration ranged from 3 weeks to 3 months. A cross-over study design that 
incorporated two 3-week intervention periods and one 2-week washout period was the most 
common study design with 21 of 26 studies (EUROLIVE, 8/21 studies; VOHF, 6/21 studies) using this 
design.  
 
 
Interventions 
There was a wide range in the polyphenol content of both the HPOO (150mg-800mg polyphenols 
per kg of oil) and LPOO (0-132mg polyphenols per kg of oil) interventions. The LPOO intervention in 
the VOHF cohort was a virgin olive oil, and the high polyphenol groups were the same oil infused 
with additional polyphenols. Al-Rewashdeh et al. 2010, as well as 5 studies from the EUROLIVE 
cohort included an additional intervention phase comprising olive oil with moderate amounts of 
polyphenols (366-368mg/kg of oil (Al-Rewashdeh 2010)); however, only the LPOO (2.7-132mg/kg) 
and HPOO (366-753mg/kg) arms were considered in this review.  
The most commonly prescribed volume of olive oil was 25ml per day (n = 16), and ranged from 
25ml-75ml per day. Additional dietary instructions varied, with most (22/26 studies) requesting 
participants restrict either high polyphenol, high antioxidant, or high vitamin E foods during the 
study intervention period. 
 
 
 
 
 
 
 
Study Results 
Oxidative stress 
Twenty studies reported on measures of oxidative stress (see Table 1). These outcomes included: 
malondialdehyde and thiobarbituric acid reactive substances (TBARS), measures of low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL) oxidation, lipid oxidation, glutathione 
peroxidase, total antioxidant capacity and antioxidant status, isoprostane excretion, protein 
carbonyl, 8-hydroxy-2'-deoxyguanosine, superoxide dismutase, catalase, ferric reducing ability of 
plasma, measures of oxidative DNA damage, paraoxonase-3 (PON-3) protein, lactonase activity, 
paraoxonase activity, hydroxy fatty acids, and conjugated dienes. 
Meta-analysis of studies with sufficient data demonstrated that HPOO significantly improved 
malondialdehyde (MD: -0.07µmol/L [95%CI: -0.12, -0.02µmol/L]; I2: 88%; p=0.004; Figure 2) and 
oxidized LDL (SMD: -0.44 [95%CI: -0.78, -0.10µmol/L]; I2: 41%; p=0.01; Figure 3) compared to LPOO. 
Sensitivity analysis did not improve the substantial heterogeneity in malondialdehyde. Pooling of 
data did not reveal a significant difference in total antioxidant capacity (SMD: 0.30 [95%CI: -0.26, 
0.86]; I2: 67%; p=0.29) (Fito et al. 2005, Salvini et al. 2006, Rus et al. 2016). A sensitivity analysis that 
removed the study by Rus et al. 2016 (the only group of participants with fibromyalgia) from analysis 
improved heterogeneity (I2: 0%); however, there was still no significant effect (MD: -0.00 [95%CI: -
0.05, 0.04]; I2: 0%; p=0.86) (Fito et al. 2005, Salvini et al. 2006). There was also no significant effect in 
glutathione peroxidase (SMD: -0.04 [95%CI-0.69, 0.61]; I2: 75%; p=0.91), and the heterogeneity was 
not improved upon sensitivity analysis. 
For results that could not be entered into a meta-analysis, compared to LPOO, HPOO significantly 
improved conjugated dienes (p=0.011), (Covas et al. 2006) glutathione peroxidase (p=0.033) (Fito et 
al. 2005), protein carbonyl (p=0.023), (Rus et al. 2016) antioxidant status (p<0.0001) (Visioli et al. 
2005), measures of oxidative DNA damage (p=0.019) and PON-3 protein (p<0.05) (Fernandez-
Castillejo et al. 2017), lactonase activity (p<0.05), (Fernandez-Castillejo et al. 2017) paraoxonase 
 
 
 
 
 
 
 
activity (p<0.05), (Fernandez-Castillejo et al. 2017) hydroxy fatty acids (p=0.038) (Covas et al. 2006). 
No other significant results were reported.  
Inflammation  
Five studies investigated the effect of HPOO on inflammatory markers compared to LPOO; (Fito et al. 
2008, Machowetz et al. 2008, Castaner et al. 2012, Moreno-Luna et al. 2012, Martin-Pelaez et al. 
2016) however, none were pooled because of heterogeneous measures reported or insufficient 
outcome and variance data. Three studies measured C-reactive protein (CRP) (Fito et al. 2008, 
Moreno-Luna et al. 2012, Martin-Pelaez et al. 2016) while interleukin-6 (IL-6), (Fito et al. 2008) 
soluble intercellular adhesion molecule-1 (sICAM-1),(Fito et al. 2008) soluble vascular adhesion 
molecule-1 (sVCAM-1), (Fito et al. 2008) monocyte chemotactic protein-1 (MCP-1), (Castaner et al. 
2012) fecal tumor necrosis factor (TNF-α), (Martin-Pelaez et al. 2016) fecal calprotectin, (Martin-
Pelaez et al. 2016) and resistin (Machowetz et al. 2008) were each measured in one study. Two 
studies reported a decrease in CRP after HPOO supplementation (p=0.024 (Fito et al. 2008) and 
p<0.001 (Moreno-Luna et al. 2012)) while one study reported an increase in CRP in the HPOO group 
(Martin-Pelaez et al. 2016). IL-6 was reduced in one study (p<0.002) (Fito et al. 2008). In one study, 
resistin was improved in the LPOO group only (Fito et al. 2008). MCP-1 also improved in one study 
(p=0.022) (Castaner et al. 2012). No significant differences were reported for all other measures.  
Blood pressure  
Five studies reported measures of blood pressure; however, participants were predominantly 
normotensive, excepting Moreno-Luna et al. 2012, in which all 48 female participants had mild 
hypertension. Meta-analysis indicated that HPOO had no effect on systolic blood pressure compared 
to LPOO (MD: -2.03mmHg [95%CI: -6.57-2.50]; I2=79%; p=0.38). There was a non-significant trend 
towards decreased diastolic blood pressure in the HPOO group (MD: -2.70mmHg [95%CI: -5.71-
0.31]; I2=78%); p=0.08 [n=1 study was removed, as comparator was not true LPOO to improve 
 
 
 
 
 
 
 
sensitivity (Martin-Pelaez et al. 2016)]); however, the effect size was small and a significant 
unexplained heterogeneity remained.   
Lipid profiles 
Twelve studies reported on measures of cholesterol levels and/or function (Ramirez-Tortosa et al. 
1999, Vissers et al. 2001, Marrugat et al. 2004, Fito et al. 2005, Visioli et al. 2005, Al-Rewashdeh 
2010, Perona et al. 2011, Hernaez et al. 2014, Farras et al. 2015, Hernáez et al. 2015, Fernandez-
Castillejo et al. 2016, Martin-Pelaez et al. 2017). These included total, LDL and HDL cholesterol; 
triglycerides; apolipoprotein B-100 (ApoB), A1 (ApoA1), and A2 (ApoA2); LDL and HDL particle size; 
HDL cholesterol efflux capacity; HDL fluidity, and cholesterol esters. 
Meta-analysis of studies with sufficient data demonstrated that HPOO significantly improved total 
cholesterol by 4.47mg/dL (95%CI: -6.54, -2.39mg/dL; p<0.0001; Figure 4). In a subgroup analysis, 
there was no significant difference in total cholesterol between healthy and CVD subgroups 
(p=0.94). Compared with LPOO, HPOO improved HDL cholesterol by 2.37mg/dL ((95%CI: 0.41, 
5.04mg/dL; p=0.02); Figure 5). The substantial heterogeneity in HDL is somewhat explained by 
subgroup analysis, where participants with CVD had significantly different outcomes than healthy 
participants (p=0.09). Healthy participants still maintained substantial heterogeneity (I2=79%) but 
HPOO groups had significantly lower HDL cholesterol compared to LPOO (by 3.95mg/dL [95%CI: 
0.89-7.01; p=0.01]; Figure 5). Conversely, the samples with CVD had no heterogeneity (I2=0%) and 
HPOO had no significant effect on HDL cholesterol in this sub-sample (MD: 0.14 [95%CI: -2.93-3.22] 
p=0.93). 
HPOO also had a non-significant trend to lower LDL cholesterol by 3.73mg/dL (95%CI: -7.60, -
0.15mg/dL; I2: 70%; p=0.06; Figure 6) compared to LPOO; however, subgroup analysis found a 
significant difference between healthy versus CVD samples (p=0.01). Similar to the HDL analysis, the 
LDL-cholesterol in the healthy samples maintained high heterogeneity (I2=71%) but was significantly 
lower by 5.31mg/dL (95%CI: -9.83- -0.79; p=0.02; Figure 6) in the HPOO groups compared to the 
 
 
 
 
 
 
 
LPOO groups. However, the samples with CVD showed no heterogeneity (I2=0%) and no effect on 
LDL cholesterol following intervention with HPOO (MD: 1.12mg/dL [95%CI: -1.30-3.53]; p=0.37). 
HPOO had no effect on plasma triglycerides compared to LPOO in a mixed sample of healthy and 
hypercholesterolemia adults (MD 0.34mg/dL (95%CI: -3.24, 3.92mg/dL; I2: 33%; p=0.85). There were 
also no significant difference between healthy versus CVD subgroups.  
 
 
For results that could not be entered into a meta-analysis, HPOO significantly improved ApoB 
(p<0.001, (Fernandez-Castillejo et al. 2016) p<0.05, (Perona et al. 2011) and p<0.03 (Hernáez et al. 
2015)), measures of LDL and/or particle size (p<0.05 (Hernáez et al. 2015) and p<0.05 (Fernandez-
Castillejo et al. 2016)), HDL cholesterol efflux capacity (p=0.042 (Hernaez et al. 2014)) and LDL 
cholesterol esters (p<0.05 (Ramirez-Tortosa et al. 1999)). 
Other measures 
Six studies reported weight or BMI outcomes, with no significant difference between interventions 
(Ramirez-Tortosa et al. 1999, Vissers et al. 2001, Moschandreas et al. 2002, Machowetz et al. 2008, 
Martin-Pelaez et al. 2016, Rus et al. 2016). Moreno-Luna et al. 2012 reported that HPOO improved 
measures of endothelial function (asymmetric dimethylarginine, hyperemic area after ischemia, and 
total plasma nitrites/nitrates) in a hypertensive cohort. Of the four studies that reported on blood 
glucose, (Marrugat et al. 2004, Fito et al. 2005, Visioli et al. 2005) one study reported an increase in 
blood glucose after HPOO consumption compared to LPOO (p=0.015) (Martin-Pelaez et al. 2016). In 
a proteomic analysis, HPOO up-regulated proteins related to cholesterol homeostasis, antioxidant 
pathways, and blood coagulation. In contrast, HPOO down-regulated proteins implicated in acute-
phase inflammatory response, lipid transport, and immune response (Pedret et al. 2015). Oxidized 
 
 
 
 
 
 
 
LDL autoantibodies (p=0.023) and pro-atherogenic gene expression (p<0.05) were also 
demonstrated to improve in two separate studies (Castaner et al. 2011, Castaner et al. 2012). 
 
 
 
 
Adverse events 
Adverse events were monitored in the VOHF and EUROLIVE study cohorts and two of the twelve 
individual studies. No adverse events were reported during their trial periods.  
Risk of Bias 
Using the Jadad Scale, most studies (15/26) received a score between 4 and 5 (out of 5), indicating a 
low risk of bias (Supplementary Material 2). The most common reason for receiving a lower score 
was due to inadequate reporting regarding withdrawals and/or dropouts and method of blinding.  
Discussion 
The results of this review indicate that olive oil polyphenols may provide cardioprotective benefits 
that are independent of the high MUFA content of olive oil. Specifically, the results of this meta-
analysis suggest that high polyphenol olive oil can improve outcomes related to cholesterol (total 
and HDL cholesterol) and oxidative stress (malondialdehyde and oxidized LDL). Furthermore, for 
measures that were unable to be included in a meta-analysis, individual studies have generally 
reported improvements in inflammation, additional measures of oxidative stress, and endothelial 
function.  
A recent systematic review and meta-analysis indicated that olive oil is superior compared to other 
plant oils in improving HDL cholesterol but not total and LDL cholesterol and triglycerides (Ghobadi 
et al. 2018). Furthermore, although the effect of polyphenol content was not examined in this 
 
 
 
 
 
 
 
review, sensitivity analyses that examined the effect of virgin olive oil compared to refined olive oil 
reported mixed outcomes. This study builds on these findings by reporting similar improvements 
that are attributed to polyphenols. 
 
 
Sensitivity analyses demonstrated that CVD risk factors such as HDL and LDL cholesterol significantly 
improved in healthy participants, while no effect was present in participants with existing CVD risk 
factors. A possible explanation for these results is that participants with CVD risk factors are likely to 
be undergoing lipid-lowering pharmacotherapy although this was not reported or controlled for in 
studies. A possible explanation for these results is that participants with CVD risk factors are likely to 
be undergoing lipid-lowering pharmacotherapy, which would make it difficult achieve additional 
reductions in CVD risk factors through dietary interventions, particularly within the short 
intervention periods (≤12 weeks) reported in these trials. Furthermore, the small effect sizes (e.g. 
HDL and LDL cholesterol) and non-significant differences (e.g. blood pressure) identified in the 
pooled analysis may be explained by there being little likelihood of large reductions in clinical 
outcomes for healthy participants with lipid profiles and blood pressure within reference range. 
Further research in participants with chronic diseases that are either not managed by 
pharmacotherapy or where the study interventions are for longer durations may report larger effect 
sizes. Furthermore, a small subset of studies assessed the functionality of cholesterol and reported 
improvements in measures such as HDL cholesterol efflux capacity. As emerging evidence suggests 
that traditional measures of HDL cholesterol may not be a reliable marker of cardiovascular health, 
(Rohatgi et al. 2014, Sacks et al. 2017) further research on functional outcomes of HDL cholesterol, 
rather than particle count, may be a more clinically relevant marker to evaluate the cardioprotective 
effects of polyphenols. 
 
 
 
 
 
 
 
As discussed in our previous review, (Marx et al. 2017) clinical trials involving polyphenol 
interventions should implement measures to control for background polyphenol intake, as this may 
influence study results. Most studies in our review provided dietary advice to control for this, 
although there was no discussion regarding adherence to this advice. The common use of a cross-
over trial design in the included studies may also provide some control for these factors. Adherence 
to the prescribed olive oil dosage was also not reported, posing an additional limitation to these 
trials. In addition, although LPOO and HPOO were directly compared in this review, there was 
considerable variability in the concentration of polyphenols and volume of olive oil prescribed for 
both groups. Therefore, total absolute daily dose varied considerably. There are also numerous 
considerations that need to be acknowledged regarding polyphenol concentration. Polyphenol 
concentrations within olive food products differ based on a variety factors including olive variety, 
soil, climate, maturation at harvest, and processing (Tripoli et al. 2005). Furthermore, there may be a 
difference in the class of polyphenols within naturally occurring high polyphenol EVOO compared to 
olive oil that has been fortified with polyphenols. Globally, the regulatory frameworks for labelling 
polyphenol concentration in foods and olive oil are lacking. With additional evidence to support the 
proposed benefits of polyphenols in EVOO, it will become increasingly important that labelling 
becomes more transparent to highlight the potential benefits to consumers. All of the reviewed 
studies, in a commonly shared strength of study design, measured and declared polyphenol 
concentration. This will assist in providing future recommendations on the concentration and 
volume of olive oil consumption required to achieve clinical benefit.  
There is evidence to suggest that the ways in which polyphenols are consumed influence total 
polyphenol bioavailability and absorption. For example, exposure to prolonged heat may deplete the 
total polyphenol content (Brenes et al. 2002). None of the studies included in this review reported 
any information related to cooking and consumption methods used by participants. Further data 
regarding the consumption of olive oil during a trial may be worthwhile investigating, to ascertain 
the potential interactions between interventions and cooking methods. This will also inform the 
 
 
 
 
 
 
 
translatability of these interventions into practical applications for prevention and management of 
CVD.  
 
 
 
While the existing research provides promising evidence for the unique benefits of olive oil 
polyphenols, additional research is warranted. Most studies were relatively short in duration with 
most intervention phases lasting on average, 3 weeks. Additional studies that evaluate the long-term 
effects of high polyphenol olive oil are required to demonstrate sustainability of health benefits. 
Furthermore, while all studies included a control group, it is possible that due to the nature of the 
intervention (i.e. distinct taste and color difference between high and low polyphenol oils), blinding 
may not have been completely effective. This is an inherent problem in many dietary intervention 
studies and future studies should implement measures to assess the adequacy of blinding measures 
such as participant interview at the end of study.  
Finally, most of the research reported herein has come from two major European cohorts (i.e. 
EUROLIVE and VOHF cohorts) and so additional research is required to replicate these findings. As 
stated in a previous review, (Hohmann et al. 2015) most studies were conducted in Mediterranean 
populations, predominantly throughout Spain, Italy, Germany, Berlin, Denmark and Finland.  
Additional studies with diverse populations and ethnicities are required to confirm the effect of high 
polyphenol olive oil. This may include investigation in of the feasibility and sustainability of regular 
EVOO consumption in non-Mediterranean populations that are not accustomed to a high 
consumption of olive oil and to determine if there are genetic differences that may predispose 
individuals to the cardiovascular benefits associated with polyphenol consumption. 
 
 
 
 
 
 
 
Conclusion 
In summary, the results of our systematic review and meta-analysis suggest that olive oil 
polyphenols provide unique cardioprotective properties, particularly for cholesterol and oxidative 
stress-related outcomes. Despite the identified beneficial properties reported in the existing studies, 
a large proportion of included studies were derived from only two cohorts. Studies were also 
conducted within a primarily Mediterranean population. Further research is needed to confirm 
these results in adequately powered, non-Mediterranean cohorts. Longer durations are also 
required to determine sustainability of health outcomes.  
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Figure 1. PRISMA Flow Diagram 
 
 
  
 
 
 
 
 
 
 
 Figure 2. Meta-analysis on the effect of HPOO on plasma malondialdehyde compared to LPOO. 
 
  
 
 
 
 
 
 
 
 Figure 3. Meta-analysis on the effect of HPOO on oxidized LDL compared to LPOO 
 
  
 
 
 
 
 
 
 
 Figure 4. Meta-analysis on the effect of HPOO on total cholesterol compared to LPOO. 
  
 
 
  
 
 
 
 
 
 
 
  
 
 
Figure 5. Meta-analysis on the effect of HPOO on LDL cholesterol compared to LPOO. 
 
 
  
 
 
 
 
 
 
 
 Figure 6. Meta-analysis on the effect of HPOO on HDL cholesterol compared to LPOO. 
 
 
 
 
 
 
 
  
 
 
Table 1. Summary Table of Included Studies (n=26) 
Author, year, country, study period  Study 
Design  
Population, 
Attrition 
rate 
Olive oil 
arms 
Duration 
and 
structure  
Results, differences between high polyphenol compared to low polyphenol olive oils*
β
 
 
Independent studies       
Ramirez-Tortosa et al. 1999, Spain. 
Study period: not reported 
Rando
mized 
Control
led, 
Cross-
over 
Trial 
n=24 free-
living men 
with 
peripheral 
vascular 
disease, 
without 
diabetes, 
hypothyroidi
sm, obesity, 
cardiac 
Dose: 
Not 
specified 
Arms: 
1. HPOO; 
800mg/k
g 
polyphen
ols  
2. LPOO; 
60mg/kg 
3-month 
interventi
ons, 3-
month 
wash-out 
period 
between 
interventi
ons (usual 
diets)   
Difference in end intervention measures between groups 
Classic CVD markers  
 
↔Weight/BMI  
↔HDL-C 
↔LDL-C  
↑ Triglycerides  
  
Lipoprotein composition of:  
Triglycerides (↔VLDL,↑ LDL, ↔HDL)  
Phospholipids (↔VLDL,↔ LDL, ↔HDL) 
 
 
 
 
 
 
 
30 
episodes 
Age 
(mean±std): 
70±2 years 
Attrition: not 
reported 
polyphen
ols  
Method: 
Instructio
n to 
replace 
usual 
saturated 
fat intake 
(butter, 
margarin
e, lard 
and 
visible fat 
on meat) 
with the 
olive oil. 
Recomm
ended to 
increase 
Total-C (↔VLDL, ↑LDL, ↔HDL) 
Cholesterol Esters (↔VLDL, ↓LDL, ↔HDL) 
Free cholesterol  (↑VLDL, ↑LDL, ↓HDL)  
 
Oxidative Stress / Antioxidant Status 
↓ Copper- mediated LDL oxidation  
↓ Macrophage uptake of oxidized LDL 
 
 
 
 
 
 
 
31 
fruits, 
legumes 
and 
vegetabl
es to 
ensure 
adequate 
intake of 
fibre and 
antioxida
nt 
vitamins.  
Restrict 
eating 
out to 
1/week. 
Advised 
to walk 
at least 1 
km/day 
 
 
 
 
 
 
 
32 
and stop 
smoking. 
Vissers et al. 2001, Netherlands. 
Study period: not reported 
Rando
mized 
Control
led, 
Cross-
over 
Trial 
Blindin
g of 
particip
ants to 
olive oil 
sequen
ce  
n=49 healthy 
adults (32 
women, 17 
men), 
Age (range):  
18-58 years, 
Attrition: 
n=6 
withdrew  
Dose: 
based on 
energy 
needs, 
mean 
69g/day  
Arms: 
1. HPOO; 
308mg/k
g 
polyphen
ols  
2. LPOO; 
43mg/kg 
polyphen
ols  
Method: 
daily 
3-week 
interventi
ons, 2-
week 
wash-out 
periods 
before 
each 
interventi
on (diets 
without 
olives, 
olive oil 
and olive 
oil 
products)  
Difference in end intervention measures between groups  
 
Classic CVD markers  
 
↔Weight  
↔Total-C  
↔HDL-C 
↔LDL-C  
↔Triglycerides  
 
Oxidative Stress / Antioxidant Status 
LDL oxidizability (↓lag time, ↔max rate) 
HDL oxidizability (↔lag time, ↔max rate) 
↔Malondialdehyde 
↔Lipid hydroperoxides 
↔Protein carbonyls 
 
 
 
 
 
 
 
33 
olive oil 
in 
provided 
foods 
(40% in 
mayonna
ise, 30% 
in sauces 
and 30% 
in 
cookies 
and 
raisin 
rolls). 
Half was 
consume
d at 
lunch in 
presence 
of 
 
 
 
 
 
 
 
34 
research
ers and 
remainde
r at 
home. 
Usual 
diet 
maintain
ed, 
except 
followed 
instructio
ns for 
low 
vitamin 
E. 
Moschandreas et al. 2002,  
Greece. 
Study period: not reported 
Rando
mized, 
single-
blind, 
n=25 Adult 
smokers (11 
men, 14 
females) 
Dose: 70 
g/day  
Arms:  
1. HPOO; 
3-week 
interventi
on, 2-
week 
Difference in change between groups  
 
Classic CVD markers 
↔Weight 
 
 
 
 
 
 
 
35 
crossov
er trial, 
Particip
ants 
were 
blinded 
to the 
type of 
oil they 
receive
d 
Age 
(mean±std): 
30±9 years   
Attrition: 
n=3 dropout 
308mg/k
g 
polyphen
ols  
2. LPOO; 
43mg/kg 
polyphen
ols 
Method: 
Oil was 
subdivide
d over 
two 
meals 
and 
participa
nts 
instructe
d to pour 
it over 
washout 
periods 
before 
each 
interventi
on (diet 
without 
olives or 
olive oil 
products) 
 
Oxidative Stress / Antioxidant Status 
Total plasma resistance to oxidation (↔lag time, ↔max rate) 
↔Protein carbonyl  
↔Malondialdehyde  
↔Lipid hydroperoxides  
↔Ferric reducing ability of plasma 
 
 
 
 
 
 
 
36 
the food 
consume
d. 
Participa
nts 
requeste
d to 
maintain 
their 
usual 
food and 
fluid 
intake 
and not 
consume 
olives 
and 
other oil-
containin
g 
 
 
 
 
 
 
 
37 
products 
Marrugat et al. 2004, 
Same cohort as Perona et al. 2011, 
Spain. 
Study period: not reported 
Placebo
-
controll
ed, 
double-
blind, 
random
ized, 
crossov
er trial  
n=33 healthy 
men 
Age 
(mean±std): 
HPOO-
MPOO-
LPOO: 55±21 
years 
MPOO-
LPOO-HPOO: 
61±19 years  
LPOO-HPOO-
MPOO: 
57±19 years 
Attrition: 3 
withdrawals  
Dose: 25 
mL/day  
Arms:  
1. HPOO: 
150mg/k
g of 
phenols 
2. 
MPOO: 
68mg/kg 
of 
phenols 
3. LPOO: 
Undetect
ed 
polyphen
ols  
Method:  
Participa
3-week 
interventi
on, 2-
week 
washout 
periods 
before 
each 
interventi
on (LPOO 
used for 
raw and 
cooking 
purposes) 
Difference in change between baseline and treatment values (change between groups not 
reported)  
 
Classic CVD markers  
↔Total-C 
↑HDL-C
HPOO
 
↔LDL-C  
↔Triglycerides  
↔Glucose   
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL
HPOO
 
Resistance of LDL to oxidation (↑lag time
HPOO,MPOO
, ↔rate, ↔max amount of dienes, 
↔antibodies against oxidized LDL  
Percentage of change (baseline to end of intervention) between groups  
 
↓Oxidized LDL
a,c
 
Resistance of LDL to oxidation (↑lag time)
a,b
 
 
 
 
 
 
 
 
38 
nts 
instructe
d to 
consume 
Treatme
nt oil 
raw, was, 
distribute
d over 3 
meals of 
the day. 
Other 
cooking 
fats were 
replaced 
by LPOO 
and 
participa
nts 
requeste
 
 
 
 
 
 
 
39 
d to 
avoid a 
high 
intake of 
foods 
listed as 
containin
g 
phenolic 
compoun
ds 
Fito et al. 2005,  
Spain. 
Study period: not reported 
Placebo 
controll
ed, 
crossov
er, 
double-
blind 
random
ized 
n=40 men 
with stable 
CHD 
Age 
(mean±std): 
67±9 years 
Attrition: 
n=3 dropped 
out, n=3 
Dose: 
50mL/da
y  
Arms: 
1. HPOO; 
161mg/k
g 
polyphen
ols  
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
Difference in change between groups 
 
Classic CVD markers 
↔Total-C 
↔LDL-C 
↔HDL-C  
↔Triglycerides  
↔Lipoprotein (a) 
↔Glucose  
 
 
 
 
 
 
 
40 
trial  excluded 
due to lack 
of 
compliance  
2. LPOO; 
14.7mg/k
g 
polyphen
ols  
Method: 
administ
ered raw 
over 3 
meals, 
other 
cooking 
fats 
replaced 
with the 
LPOO 
during 
both 
intervent
ions  
on (LPOO 
as source 
of crude 
fat) 
↓SBP  
↔DBP  
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL-C  
↔ Antibodies against oxidized 
↓Lipoperoxides  
↑Glutathione peroxidase  
↔Total antioxidant status 
 
 
 
 
 
 
 
41 
Visioli et al. 2005, Italy. 
Study period: not reported 
Rando
mized, 
single-
blind, 
crossov
er trial.  
Laborat
ory 
person
nel 
were 
blinded 
to 
treatm
ents 
n=22 mildly 
dyslipidaemi
c adults (12 
men, 10 
females) 
Age (range):  
18 to 65 
years  
Attrition: not 
reported  
Dose: 40 
mL/ day 
Arms: 
1. HPOO; 
total 
hydroxyt
yrosol 
content 
166 mg/L  
2. LPOO; 
total 
hydroxyt
yrosol 
content 2 
mg/L 
Method: 
Raw olive 
oil was 
subdivide
d 
7-week 
interventi
on, 3-
week 
washout 
period 
prior to 
commenc
ement, 4-
week 
washout 
period 
between 
interventi
ons (40 
mL/day of 
LPOO) 
Difference in change between groups 
 
Classic CVD markers  
↔Total-C 
↔HDL-C 
↔LDL-C  
↔Triglycerides  
↔ BMI 
↔ Mean blood pressure  
↔ Glucose  
 
Oxidative Stress / Antioxidant Status 
↑Antioxidant capacity 
↓Thromboxane B2 (TXB2)   
↔Isoprostane excretion (8-iso-PGF2α) 
 
 
 
 
 
 
 
 
42 
between 
lunch 
and 
dinner 
and 
participa
nts 
instructe
d to 
consume 
with 
pasta or 
vegetabl
es. Other 
polyphen
ol-rich 
foods in 
the diet 
were 
controlle
 
 
 
 
 
 
 
43 
d for 
Salvini et al. 2006, Italy. 
Study period: September–November 
2002 to  January – March 2003 
Rando
mized, 
double-
blind, 
crossov
er trial  
 
  
n=10 healthy 
postmenopa
usal women  
Age (range):  
47 to 67 
years 
Attrition: 
n=2 dropout 
Dose: 50 
g/day  
Arms:  
1. HPOO: 
592 
mg/kg 
polyphen
ols 
2. LPOO: 
147 
mg/kg 
polyphen
ols  
Method: 
Participa
nts 
instructe
d to 
substitut
8-week 
interventi
on, 8-
week 
washout 
period 
(habitual 
fats and 
oils) 
Difference in change between groups  
 
Oxidative Stress / Antioxidant Status 
Oxidative DNA damage (↓oxidized DNA bases, ↔basal DNA breaks) 
↔Total Antioxidant Status 
↔DNA breakage induced by H2O2 (in vitro) 
 
 
 
 
 
 
 
44 
e all fats 
and oils 
with the 
study oil 
and to 
consume 
at least 
50 g daily 
in raw 
form in 
addition 
to the oil 
necessar
y for 
cooking. 
Apart 
from the 
fat 
substituti
on, 
 
 
 
 
 
 
 
45 
participa
nts 
instructe
d to stay 
on their 
habitual 
diet 
Fito et al. 2008, 
Subset of Fito et al. 2005,  
Spain. 
Study period: not reported 
Placebo 
controll
ed, 
crossov
er, 
double-
blind 
random
ised 
trial  
n=28 men 
with stable 
CHD 
Age 
(mean±std): 
68±7 years 
Attrition: not 
reported  
Dose: 
50mL/da
y  
Arms: 
1. HPOO; 
161mg/k
g 
polyphen
ols  
2. LPOO; 
14.7mg/k
g 
polyphen
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on (LPOO 
as source 
of crude 
fat) 
Difference in change between groups 
 
Inflammatory markers 
↓CRP  
↓IL-6  
↔sICAM-1  
↔sVCAM-1 
 
 
 
 
 
 
 
46 
ols  
Method: 
administ
ered raw 
over 3 
meals, 
other 
cooking 
fats 
replaced 
with the 
LPOO 
during 
both 
intervent
ions  
 
Al-Rewashdeh, 2010, Jordan. 
Study period: October 2008 to March 
2009 
Control
led, 
Cross-
over 
n=25 healthy 
adults (12 
men, 13 
women)  
Dose: 
Not 
prescribe
d, 
4-week 
interventi
ons, 4-
week 
Difference in change between groups 
  
Classic CVD markers  
↑HDL-C 
 
 
 
 
 
 
 
47 
Trial  Age(range): 
37 to 50 
years (men), 
33 to 44 
years 
(women)  
Attrition: not 
reported  
consume
d about 
70g per 
day  
Arms: 
1. HPOO; 
753mg/k
g 
polyphen
ols  
2. 
MPOO; 
368mg/k
g 
polyphen
ols  
3. LPOO; 
132mg/k
g 
polyphen
wash out 
periods 
before 
each 
interventi
on 
(habitual 
diet with 
use of 
usual fats 
hydrogen
ated, 
refined oil 
and blend 
of seed 
oils) 
↓LDL-C
abc
  
↓Total /HDL-C
abc
 
↓LDL /HDL-C
abc 
 
↔Triglycerides  
↔Phospholipids  
↔Total-C 
↔Free cholesterol  
↔Cholesterol Ester 
↓SBP
ab
 (men only)  
↓DBP
ab
 
 
Oxidative Stress / Antioxidant Status 
↓Malondialdehyde
abc
 
 
 
 
 
 
 
 
48 
ols 
Method: 
Habitual 
diets plus 
intervent
ion to 
replace 
usual fat 
intake in 
cooking, 
salad 
dressing, 
and on 
bread  
Perona et al. 2011. 
Same cohort as Marrugat et al. 2004, 
Spain. 
Study period: not reported 
Placebo
-
controll
ed, 
double-
blind, 
n=33 healthy 
men 
Age(range):  
23 to 91 
years   
Attrition: 3 
Dose: 25 
mL/day  
1. HPOO: 
825 
mmol 
caffeic 
3-week 
interventi
on, 2-
week 
washout 
periods 
Difference in change between groups  
 
Classic CVD markers 
Serum lipid concentrations  
↔Total-C 
↔Triglycerides  
 
 
 
 
 
 
 
49 
random
ized, 
crossov
er trial  
withdrawals  acid 
equivale
nts/kg 
2. 
MPOO: 
370 
mmol 
caffeic 
acid 
equivale
nts/kg 
3. LPOO: 
0 mmol 
caffeic 
acid 
equivale
nts/kg 
Method: 
Participa
nts 
before 
each 
interventi
on (LPOO 
used for 
raw and 
cooking 
purposes) 
↓VLDL-cholesteryl esters
c
 
↓VLDL-Triglycerides
a,c 
 
↓VLDL-C
a,c 
 
↓VLDL-Phospholipids
a,c
  
↓VLDL-Apolioprotein B
a,b
 
↑VLDL Triglyceride/Apoliprotein B ratio
a,b
 
 
 
 
 
 
 
 
50 
instructe
d to 
consume 
treatmen
t oil raw, 
distribute
d over 3 
meals of 
the day. 
Other 
cooking 
fats were 
replaced 
by LPOO 
and 
participa
nts 
requeste
d to 
avoid a 
 
 
 
 
 
 
 
51 
high 
intake of 
foods 
listed as 
containin
g 
phenolic 
compoun
ds 
Moreno-Luna et al. 2012,  
Spain. 
Study period: not reported 
Rando
mized, 
single-
blind, 
crossov
er trial  
n=24 women 
with high-
normal BP or 
stage 1 
essential 
hypertension 
Age (Range):  
24 to 27 
years  
Attrition: 
n=10 
Dose: 60 
mL/day  
1. HPOO: 
564mg/k
g 
2. LPOO: 
0mg/kg 
Method: 
Mediterr
anean-
style diet 
2-month 
interventi
on, 4-
month 
washout 
period 
prior to 
commenc
ement, 4 
week 
washout 
Difference in change between baseline and treatment values (change between groups not 
reported) 
 
Classic CVD markers  
↓SBP
HPOO
 
↓DBP
HPOO 
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL
HPOO 
 
Inflammatory markers 
 
 
 
 
 
 
 
52 
dropout  in 
addition 
to the 
treatmen
t oil were 
prescribe
d. 
Participa
nts 
instructe
d to 
avoid 
foods 
classified 
as highly 
rich in 
polyphen
ols 
period 
between 
interventi
ons 
(provided 
a set 
menu 
plan 
[Mediterr
anean-
style diet] 
containin
g the 
same 
calories as 
their 
habitual 
diets and 
sunflower 
or corn oil 
↓hs-CRP
HPOO 
 
Additional outcomes 
Endothelial function measures 
(↓Asymmetric dimethylarginine
HPOO
 
↑Hyperemic area after ischemia
HPOO 
 
↑Total plasma nitrites/ nitrates
HPOO
) 
 
 
 
 
 
 
 
53 
was 
permitted
)  
Rus et al. 2017,  
Spain. 
Study period: not reported 
Rando
mized, 
controll
ed, 
double-
blind, 
parallel 
trial  
n=23 women 
with 
fibromyalgia 
Age 
(mean±std): 
HPOO; 54±6 
years, LPOO; 
48±8 years 
Attrition: not 
reported  
Dose: 50 
mL/day  
Arms:  
1. HPOO 
(n=11); 
polyphen
ol 
content 
not 
reported 
2. LPOO 
(n=12); 
polyphen
ol 
content 
not 
reported 
3-week 
interventi
on, 2-
week 
washout 
period 
prior to 
commenc
ement (50 
mL/day 
LPOO) 
Difference in change between groups  
 
Classic CVD markers 
↔BMI  
↔SBP 
↔DBP 
↔Cardiac frequency(bpm)  
 
Oxidative status 
↓Thiobarbituric acid reactive substances (TBARS) 
↓Protein carbonyl content 
↔8-hydroxy-2'-deoxyguanosine 
Antioxidant status 
↔Total antioxidant capacity 
↔Superoxide dismutase (SOD) 
↔Glutathione peroxidase (GPx) 
↔Catalase  
 
 
 
 
 
 
 
54 
Method: 
Treatme
nt olive 
oil was 
consume
d raw but 
LPOO 
was used 
for 
cooking. 
Intake of 
antioxida
nts was 
normaliz
ed and 
participa
nts 
recomme
nded to 
avoid an 
↔Antioxidant compounds (copper, zinc, ceruloplasmin, iron, ferritin, transferrin, uric acid, 
albumin, bilirubin) 
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excess of 
calories 
and/or 
lipids 
VOHF Cohort          
Farras et al. 2015,  
Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=33 
hypercholest
erolemic 
adults (19 
men, 14 
women) 
Age (range):  
35 to 80 
years 
Attrition: 
n=3 
discontinued 
trial 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
Difference in end intervention measures between groups (controlled for baseline values) 
 
Classic CVD markers  
↔ HDL composition (total-C, triglycerides, Apo-A1, Apo-AII, free cholesterol, esterified-
cholesterol, phospholipids, free cholesterol/total-C, esterified cholesterol/total-C, 
phospholipids/free cholesterol, esterified cholesterol/free cholesterol) 
 
 
 
 
 
 
 
56 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
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ol-rich 
food. 
Pedret et al. 2015, Spain. 
Study period: April 2012 to September 
2012  
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=33 
hypercholest
erolemic 
adults (19 
men, 14 
women),  
Age (range):  
35 to 80 
years 
Attrition: 
n=3 
discontinued 
trial 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
Additional outcomes 
All interventions upregulated proteins related to cholesterol homeostasis, protection against 
oxidation and blood coagulation, while down-regulating proteins related to in acute-phase 
response, lipid transport, and immune response. 
HPOO had a stronger effect on the following proteins: PON-3 and PPBP which were up-
regulated. 
 
 
 
 
 
 
 
58 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
Fernandez-Castillejo et al. 2016, Spain.  Double- n=33 Dose: 25 3-week Difference in change between groups 
 
 
 
 
 
 
 
59 
Study period: April 2012 to September 
2012  
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
hypercholest
erolemic 
adults  (19 
men, 14 
women) 
Age (range):  
35 to 80 
years 
Attrition: 
n=3 
discontinued 
trial 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
 
Classic CVD markers  
↓LDL-C 
↔ApoB100 
NMR LDL particle concentration (↓total, ↓IDL, ↔large, ↔small)  
 
↔HDL-C  
↔ApoA1 
NMR HDL particle concentration (↓total, ↑large, ↔medium, ↓small) and ↑size  
 
↔Triglycerides  
↔VLDL Triglycerides  
NMR VLDL particle concentration (↔total, ↔large, ↓medium, ↔small) and ↓size  
 
↓ApoB100 containing lipoproteins 
 
↓LDL particles /HDL particles   
↓HDL-C/HDL particles  
↓small HDL/ large HDL 
↓Lipoprotein insulin resistance index  
 
 
 
 
 
 
 
60 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol rich 
food. 
Martin-Pelaez et al. 2016, Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
n=10 
hypercholest
erolemic 
adults (5 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
3-week 
interventi
on period, 
2-week 
Difference in change between groups  
 
Classic CVD markers  
↔Weight/BMI  
 
 
 
 
 
 
 
61 
controll
ed, 
crossov
er 
clinical 
trial 
men, 5 
women) 
Age (range):  
35 to 80 
years 
Attrition: not 
reported  
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
↔Waist circumference  
↑Glucose  
↔SBP 
↔DBP 
 
Oxidative status 
↔ Oxidized LDL-C 
 
Inflammatory markers 
↑CRP 
↔Fecal TNF-α 
↔Fecal calprotectin 
 
Additional markers 
↑Total fecal bacteria  
↔Ratio Firmicutes/Bacteroidetes 
↔Fecal IgA coated bacteria  
↔Fecal IgA 
 
 
 
 
 
 
 
62 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
Fernandez-Castillejo et al. 2017, Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
controll
ed, 
crossov
n=33 
hypercholest
erolemic 
adults (19 
men, 14 
women) 
Age (range):  
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
Difference in change between groups 
 
Oxidative status 
↑ PON-3 protein  
↔PON-1 protein  
Lactonase activity (↓ raw, ↔ specific) 
Paraoxonase activity (less ↑ raw, ↔ specific)    
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er 
clinical 
trial 
35 to 80 
years 
Attrition: not 
reported  
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
each 
interventi
on 
("commo
n" olive 
oil) 
 
 
 
 
 
 
 
64 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
Martin-Pelaez et al. 2017,  
Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=12 
hypercholest
erolemic 
adults  (7 
men, 5 
women)  
Age (range):  
46 to 67 
years 
Attrition: not 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
Difference in change between groups  
 
Classic CVD markers  
↔Total-C  
 
Oxidative status 
↔ Oxidized LDL-C 
 
Additional markers 
↔ Bacterial Enumerations 
 
 
 
 
 
 
 
65 
reported  2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Advised 
to limit 
("commo
n" olive 
oil) 
↔ Short chain fatty acids  
↔ Neutral sterols 
 ↔Bile acids  
 
 
 
 
 
 
 
66 
consump
tion 
polyphen
ol-rich 
food. 
EUROLIVE Cohort     
Covas et al. 2006. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=200 
healthy men 
Age (range):  
20 to 60 
years 
Attrition: 
n=18 
dropout 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
Difference in change between groups 
 
Oxidative status 
↓Conjugated dienes
b,c
  
↓Hydroxy fatty acids
c
 
↓Oxidized LDL-C
c
  
↔F2α-isoprostanes 
 
 
 
 
 
 
 
67 
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts asked 
to avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
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vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Machowetz et al. 2007. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003  
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=200 
healthy men 
Age(range):  
20 to 60 
years 
Attrition: 
n=18 
dropout 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
Difference in change between groups  
 
Oxidative status 
↔Markers of DNA /RNA oxidative damage (urinary excretion rates of guanine, guanosine, and 
deoxyguanosine and their corresponding oxidation products) 
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164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
olive and 
olive oil 
consumpt
ion) 
 
 
 
 
 
 
 
70 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Machowetz et al. 2008. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
Single 
centre, 
double-
blind, 
n=38 healthy 
men 
Age(mean±st
d): 36±2 
Dose: 25 
mL  
Arms: 
1. LPOO; 
3-week 
interventi
ons, 2-
week 
Difference in change between groups  
 
Classic CVD markers  
↔BMI   
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2003 random
ized, 
crossov
er, 
controll
ed trial 
years 
Attrition: not 
reported 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
 
Inflammatory markers 
↓resistin
LPOO
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ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
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and 
beer). 
de la Torre-Carbot et al. 2010.  
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
nter, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=36 
nonsmoking 
males 
Age (range):  
20 to 60 
years 
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
Difference in change between baseline and treatment values (change between groups not 
reported) 
 
Oxidative status 
↓plasma oxLDL 
 
 
 
 
 
 
 
 
 
74 
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
 
 
 
 
 
 
 
75 
and 
beer). 
Castaner et al. 2011. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=200 
healthy men 
Age(range):  
20 to 60 
years 
Attrition: 
n=18 
dropout 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
Difference changes between each arm of the study (dose dependent increase related to 
polyphenol content of olive oil): 
 
Oxidative status 
↑ OLAB 
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ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Castaner et al. 2012. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=18 healthy 
men 
Age(mean±st
d): 38±12 
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
Difference in change between groups  
 
Inflammatory markers 
↓MCP1 
 
Difference changes between baseline and treatment values: 
 
Additional markers 
↓Atherosclerosis-related gene expression (CD40L, IL23A, IL7R, IL8RA, and OLR1 genes) 
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ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
consumpt
ion) 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Hernaez et al. 2014. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=47 healthy 
men  
Age 
(mean±std): 
30±9 years   
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
Difference in change between groups  
  
Classic CVD markers  
↔Phospholipids 
↔Apolipoprotein A1 and A2  
 
↑ HDL cholesterol efflux capacity 
↑large HDL2 particles 
↔HDL particle count 
↔Triglycerides in HDL core 
↔HDL fluidity 
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ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
consumpt
ion) 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Hernaez et al. 2015. 
3 Cities (Potsdam, Germany; Kupio 
Finland, Barcelona, Spain) 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=25 Healthy 
men (lipid-
related 
outcomes) 
Age 
(mean±std): 
32±11 years 
n=18 Healthy 
men (gene 
expression 
outcomes) 
Age 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
Difference in change between groups  
 
Classic CVD markers  
↓Apolipoprotein B-100  
↓Total LDL particles  
↓Small LDL particles  
↔Large LDL particles 
↔Lipoprotein Lipase gene expression 
 
Oxidative status 
↔LDL oxidation lag time  
↔LDL oxidation rate 
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(mean±std): 
37±12 years 
Attrition: not 
reported 
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
consumpt
ion) 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
 
 
Author, year, country, study period  Study 
Design  
Population, 
Attrition 
rate 
Olive oil 
arms 
Duration 
and 
structure  
Results, differences between high polyphenol compared to low polyphenol olive oils*
β
 
 
Independent studies       
Ramirez-Tortosa et al. 1999, Spain. 
Study period: not reported 
Rando
mized 
Control
led, 
Cross-
n=24 free-
living men 
with 
peripheral 
vascular 
Dose: 
Not 
specified 
Arms: 
1. HPOO; 
3-month 
interventi
ons, 3-
month 
wash-out 
Difference in end intervention measures between groups 
Classic CVD markers  
 
↔Weight/BMI  
↔HDL-C 
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over 
Trial 
disease, 
without 
diabetes, 
hypothyroidi
sm, obesity, 
cardiac 
episodes 
Age 
(mean±std): 
70±2 years 
Attrition: not 
reported 
800mg/k
g 
polyphen
ols  
2. LPOO; 
60mg/kg 
polyphen
ols  
Method: 
Instructio
n to 
replace 
usual 
saturated 
fat intake 
(butter, 
margarin
e, lard 
and 
visible fat 
period 
between 
interventi
ons (usual 
diets)   
↔LDL-C  
↑ Triglycerides  
  
Lipoprotein composition of:  
Triglycerides (↔VLDL,↑ LDL, ↔HDL)  
Phospholipids (↔VLDL,↔ LDL, ↔HDL) 
Total-C (↔VLDL, ↑LDL, ↔HDL) 
Cholesterol Esters (↔VLDL, ↓LDL, ↔HDL) 
Free cholesterol  (↑VLDL, ↑LDL, ↓HDL)  
 
Oxidative Stress / Antioxidant Status 
↓ Copper- mediated LDL oxidation  
↓ Macrophage uptake of oxidized LDL 
 
 
 
 
 
 
 
85 
on meat) 
with the 
olive oil. 
Recomm
ended to 
increase 
fruits, 
legumes 
and 
vegetabl
es to 
ensure 
adequate 
intake of 
fibre and 
antioxida
nt 
vitamins.  
Restrict 
eating 
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out to 
1/week. 
Advised 
to walk 
at least 1 
km/day 
and stop 
smoking. 
Vissers et al. 2001, Netherlands. 
Study period: not reported 
Rando
mized 
Control
led, 
Cross-
over 
Trial 
Blindin
g of 
particip
ants to 
olive oil 
n=49 healthy 
adults (32 
women, 17 
men), 
Age (range):  
18-58 years, 
Attrition: 
n=6 
withdrew  
Dose: 
based on 
energy 
needs, 
mean 
69g/day  
Arms: 
1. HPOO; 
308mg/k
g 
polyphen
ols  
3-week 
interventi
ons, 2-
week 
wash-out 
periods 
before 
each 
interventi
on (diets 
without 
olives, 
Difference in end intervention measures between groups  
 
Classic CVD markers  
 
↔Weight  
↔Total-C  
↔HDL-C 
↔LDL-C  
↔Triglycerides  
 
Oxidative Stress / Antioxidant Status 
LDL oxidizability (↓lag time, ↔max rate) 
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sequen
ce  
2. LPOO; 
43mg/kg 
polyphen
ols  
Method: 
daily 
olive oil 
in 
provided 
foods 
(40% in 
mayonna
ise, 30% 
in sauces 
and 30% 
in 
cookies 
and 
raisin 
rolls). 
olive oil 
and olive 
oil 
products)  
HDL oxidizability (↔lag time, ↔max rate) 
↔Malondialdehyde 
↔Lipid hydroperoxides 
↔Protein carbonyls 
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Half was 
consume
d at 
lunch in 
presence 
of 
research
ers and 
remainde
r at 
home. 
Usual 
diet 
maintain
ed, 
except 
followed 
instructio
ns for 
low 
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vitamin 
E. 
Moschandreas et al. 2002,  
Greece. 
Study period: not reported 
Rando
mized, 
single-
blind, 
crossov
er trial, 
Particip
ants 
were 
blinded 
to the 
type of 
oil they 
receive
d 
n=25 Adult 
smokers (11 
men, 14 
females) 
Age 
(mean±std): 
30±9 years   
Attrition: 
n=3 dropout 
Dose: 70 
g/day  
Arms:  
1. HPOO; 
308mg/k
g 
polyphen
ols  
2. LPOO; 
43mg/kg 
polyphen
ols 
Method: 
Oil was 
subdivide
d over 
two 
meals 
3-week 
interventi
on, 2-
week 
washout 
periods 
before 
each 
interventi
on (diet 
without 
olives or 
olive oil 
products) 
Difference in change between groups  
 
Classic CVD markers 
↔Weight 
 
Oxidative Stress / Antioxidant Status 
Total plasma resistance to oxidation (↔lag time, ↔max rate) 
↔Protein carbonyl  
↔Malondialdehyde  
↔Lipid hydroperoxides  
↔Ferric reducing ability of plasma 
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and 
participa
nts 
instructe
d to pour 
it over 
the food 
consume
d. 
Participa
nts 
requeste
d to 
maintain 
their 
usual 
food and 
fluid 
intake 
and not 
 
 
 
 
 
 
 
91 
consume 
olives 
and 
other oil-
containin
g 
products 
Marrugat et al. 2004, 
Same cohort as Perona et al. 2011, 
Spain. 
Study period: not reported 
Placebo
-
controll
ed, 
double-
blind, 
random
ized, 
crossov
er trial  
n=30 healthy 
men 
Age 
(mean±std): 
HPOO-
MPOO-
LPOO: 55±21 
years 
MPOO-
LPOO-HPOO: 
61±19 years  
LPOO-HPOO-
MPOO: 
Dose: 25 
mL/day  
Arms:  
1. HPOO: 
150mg/k
g of 
phenols 
2. 
MPOO: 
68mg/kg 
of 
phenols 
3. LPOO: 
3-week 
interventi
on, 2-
week 
washout 
periods 
before 
each 
interventi
on (LPOO 
used for 
raw and 
cooking 
Difference in change between baseline and treatment values (change between groups not 
reported)  
 
Classic CVD markers  
↔Total-C 
↑HDL-C
HPOO
 
↔LDL-C  
↔Triglycerides  
↔Glucose   
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL
HPOO
 
Resistance of LDL to oxidation (↑lag time
HPOO,MPOO
, ↔rate, ↔max amount of dienes, 
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57±19 years 
Attrition: 3 
withdrawals  
Undetect
ed 
polyphen
ols  
Method:  
Participa
nts 
instructe
d to 
consume 
Treatme
nt oil 
raw, was, 
distribute
d over 3 
meals of 
the day. 
Other 
cooking 
fats were 
purposes) ↔antibodies against oxidized LDL  
Percentage of change (baseline to end of intervention) between groups  
 
↓Oxidized LDL
a,c
 
Resistance of LDL to oxidation (↑lag time)
a,b
 
 
 
 
 
 
 
 
93 
replaced 
by LPOO 
and 
participa
nts 
requeste
d to 
avoid a 
high 
intake of 
foods 
listed as 
containin
g 
phenolic 
compoun
ds 
Fito et al. 2005,  
Spain. 
Study period: not reported 
Placebo 
controll
ed, 
n=40 men 
with stable 
CHD 
Dose: 
50mL/da
y  
3-week 
interventi
on period, 
Difference in change between groups 
 
Classic CVD markers 
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crossov
er, 
double-
blind 
random
ized 
trial  
Age 
(mean±std): 
67±9 years 
Attrition: 
n=3 dropped 
out, n=3 
excluded 
due to lack 
of 
compliance  
Arms: 
1. HPOO; 
161mg/k
g 
polyphen
ols  
2. LPOO; 
14.7mg/k
g 
polyphen
ols  
Method: 
administ
ered raw 
over 3 
meals, 
other 
cooking 
fats 
replaced 
2-week 
washout 
periods 
before 
each 
interventi
on (LPOO 
as source 
of crude 
fat) 
↔Total-C 
↔LDL-C 
↔HDL-C  
↔Triglycerides  
↔Lipoprotein (a) 
↔Glucose  
↓SBP  
↔DBP  
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL-C  
↔ Antibodies against oxidized 
↓Lipoperoxides  
↑Glutathione peroxidase  
↔Total antioxidant status 
 
 
 
 
 
 
 
95 
with the 
LPOO 
during 
both 
intervent
ions  
Visioli et al. 2005, Italy. 
Study period: not reported 
Rando
mized, 
single-
blind, 
crossov
er trial.  
Laborat
ory 
person
nel 
were 
blinded 
to 
treatm
n=22 mildly 
dyslipidaemi
c adults (12 
men, 10 
females) 
Age (range):  
18 to 65 
years  
Attrition: not 
reported  
Dose: 40 
mL/ day 
Arms: 
1. HPOO; 
total 
hydroxyt
yrosol 
content 
166 mg/L  
2. LPOO; 
total 
hydroxyt
yrosol 
content 2 
7-week 
interventi
on, 3-
week 
washout 
period 
prior to 
commenc
ement, 4-
week 
washout 
period 
between 
interventi
Difference in change between groups 
 
Classic CVD markers  
↔Total-C 
↔HDL-C 
↔LDL-C  
↔Triglycerides  
↔ BMI 
↔ Mean blood pressure  
↔ Glucose  
 
Oxidative Stress / Antioxidant Status 
↑Antioxidant capacity 
↓Thromboxane B2 (TXB2)   
 
 
 
 
 
 
 
96 
ents mg/L 
Method: 
Raw olive 
oil was 
subdivide
d 
between 
lunch 
and 
dinner 
and 
participa
nts 
instructe
d to 
consume 
with 
pasta or 
vegetabl
es. Other 
ons (40 
mL/day of 
LPOO) 
↔Isoprostane excretion (8-iso-PGF2α) 
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polyphen
ol-rich 
foods in 
the diet 
were 
controlle
d for 
Salvini et al. 2006, Italy. 
Study period: September–November 
2002 to  January – March 2003 
Rando
mized, 
double-
blind, 
crossov
er trial  
 
  
n=10 healthy 
postmenopa
usal women  
Age (range):  
47 to 67 
years 
Attrition: 
n=2 dropout 
Dose: 50 
g/day  
Arms:  
1. HPOO: 
592 
mg/kg 
polyphen
ols 
2. LPOO: 
147 
mg/kg 
polyphen
ols  
8-week 
interventi
on, 8-
week 
washout 
period 
(habitual 
fats and 
oils) 
Difference in change between groups  
 
Oxidative Stress / Antioxidant Status 
Oxidative DNA damage (↓oxidized DNA bases, ↔basal DNA breaks) 
↔Total Antioxidant Status 
↔DNA breakage induced by H2O2 (in vitro) 
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Method: 
Participa
nts 
instructe
d to 
substitut
e all fats 
and oils 
with the 
study oil 
and to 
consume 
at least 
50 g daily 
in raw 
form in 
addition 
to the oil 
necessar
y for 
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cooking. 
Apart 
from the 
fat 
substituti
on, 
participa
nts 
instructe
d to stay 
on their 
habitual 
diet 
Fito et al. 2008, 
Subset of Fito et al. 2005,  
Spain. 
Study period: not reported 
Placebo 
controll
ed, 
crossov
er, 
double-
blind 
n=28 men 
with stable 
CHD 
Age 
(mean±std): 
68±7 years 
Attrition: not 
Dose: 
50mL/da
y  
Arms: 
1. HPOO; 
161mg/k
g 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
Difference in change between groups 
 
Inflammatory markers 
↓CRP  
↓IL-6  
↔sICAM-1  
↔sVCAM-1 
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random
ised 
trial  
reported  polyphen
ols  
2. LPOO; 
14.7mg/k
g 
polyphen
ols  
Method: 
administ
ered raw 
over 3 
meals, 
other 
cooking 
fats 
replaced 
with the 
LPOO 
during 
both 
each 
interventi
on (LPOO 
as source 
of crude 
fat) 
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intervent
ions  
Al-Rewashdeh, 2010, Jordan. 
Study period: October 2008 to March 
2009 
Control
led, 
Cross-
over 
Trial  
n=25 healthy 
adults (12 
men, 13 
women)  
Age(range): 
37 to 50 
years (men), 
33 to 44 
years 
(women)  
Attrition: not 
reported  
Dose: 
Not 
prescribe
d, 
consume
d about 
70g per 
day  
Arms: 
1. HPOO; 
753mg/k
g 
polyphen
ols  
2. 
MPOO; 
368mg/k
g 
4-week 
interventi
ons, 4-
week 
wash out 
periods 
before 
each 
interventi
on 
(habitual 
diet with 
use of 
usual fats 
hydrogen
ated, 
refined oil 
and blend 
Difference in change between groups 
  
Classic CVD markers  
↑HDL-C 
↓LDL-C
abc
  
↓Total /HDL-C
abc
 
↓LDL /HDL-C
abc 
 
↔Triglycerides  
↔Phospholipids  
↔Total-C 
↔Free cholesterol  
↔Cholesterol Ester 
↓SBP
ab
 (men only)  
↓DBP
ab
 
 
Oxidative Stress / Antioxidant Status 
↓Malondialdehyde
abc
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polyphen
ols  
3. LPOO; 
132mg/k
g 
polyphen
ols 
Method: 
Habitual 
diets plus 
intervent
ion to 
replace 
usual fat 
intake in 
cooking, 
salad 
dressing, 
and on 
bread  
of seed 
oils) 
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Perona et al. 2011. 
Same cohort as Marrugat et al. 2004, 
Spain. 
Study period: not reported 
Placebo
-
controll
ed, 
double-
blind, 
random
ized, 
crossov
er trial  
n=33 healthy 
men 
Age(range):  
23 to 91 
years   
Attrition: 3 
withdrawals  
Dose: 25 
mL/day  
1. HPOO: 
825 
mmol 
caffeic 
acid 
equivale
nts/kg 
2. 
MPOO: 
370 
mmol 
caffeic 
acid 
equivale
nts/kg 
3. LPOO: 
0 mmol 
caffeic 
3-week 
interventi
on, 2-
week 
washout 
periods 
before 
each 
interventi
on (LPOO 
used for 
raw and 
cooking 
purposes) 
Difference in change between groups  
 
Classic CVD markers 
Serum lipid concentrations  
↔Total-C 
↔Triglycerides  
↓VLDL-cholesteryl esters
c
 
↓VLDL-Triglycerides
a,c 
 
↓VLDL-C
a,c 
 
↓VLDL-Phospholipids
a,c
  
↓VLDL-Apolioprotein B
a,b
 
↑VLDL Triglyceride/Apoliprotein B ratio
a,b
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acid 
equivale
nts/kg 
Method: 
Participa
nts 
instructe
d to 
consume 
treatmen
t oil raw, 
distribute
d over 3 
meals of 
the day. 
Other 
cooking 
fats were 
replaced 
by LPOO 
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and 
participa
nts 
requeste
d to 
avoid a 
high 
intake of 
foods 
listed as 
containin
g 
phenolic 
compoun
ds 
Moreno-Luna et al. 2012,  
Spain. 
Study period: not reported 
Rando
mized, 
single-
blind, 
crossov
n=24 women 
with high-
normal BP or 
stage 1 
essential 
Dose: 60 
mL/day  
1. HPOO: 
564mg/k
g 
2-month 
interventi
on, 4-
month 
washout 
Difference in change between baseline and treatment values (change between groups not 
reported) 
 
Classic CVD markers  
↓SBP
HPOO
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er trial  hypertension 
Age (Range):  
24 to 27 
years  
Attrition: 
n=10 
dropout  
2. LPOO: 
0mg/kg 
Method: 
Mediterr
anean-
style diet 
in 
addition 
to the 
treatmen
t oil were 
prescribe
d. 
Participa
nts 
instructe
d to 
avoid 
foods 
classified 
period 
prior to 
commenc
ement, 4 
week 
washout 
period 
between 
interventi
ons 
(provided 
a set 
menu 
plan 
[Mediterr
anean-
style diet] 
containin
g the 
same 
↓DBP
HPOO 
 
Oxidative Stress / Antioxidant Status 
↓Oxidized LDL
HPOO 
 
Inflammatory markers 
↓hs-CRP
HPOO 
 
Additional outcomes 
Endothelial function measures 
(↓Asymmetric dimethylarginine
HPOO
 
↑Hyperemic area after ischemia
HPOO 
 
↑Total plasma nitrites/ nitrates
HPOO
) 
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as highly 
rich in 
polyphen
ols 
calories as 
their 
habitual 
diets and 
sunflower 
or corn oil 
was 
permitted
)  
Rus et al. 2017,  
Spain. 
Study period: not reported 
Rando
mized, 
controll
ed, 
double-
blind, 
parallel 
trial  
n=23 women 
with 
fibromyalgia 
Age 
(mean±std): 
HPOO; 54±6 
years, LPOO; 
48±8 years 
Attrition: not 
reported  
Dose: 50 
mL/day  
Arms:  
1. HPOO 
(n=11); 
polyphen
ol 
content 
not 
reported 
2. LPOO 
3-week 
interventi
on, 2-
week 
washout 
period 
prior to 
commenc
ement (50 
mL/day 
LPOO) 
Difference in change between groups  
 
Classic CVD markers 
↔BMI  
↔SBP 
↔DBP 
↔Cardiac frequency(bpm)  
 
Oxidative status 
↓Thiobarbituric acid reactive substances (TBARS) 
↓Protein carbonyl content 
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(n=12); 
polyphen
ol 
content 
not 
reported 
Method: 
Treatme
nt olive 
oil was 
consume
d raw but 
LPOO 
was used 
for 
cooking. 
Intake of 
antioxida
nts was 
normaliz
↔8-hydroxy-2'-deoxyguanosine 
Antioxidant status 
↔Total antioxidant capacity 
↔Superoxide dismutase (SOD) 
↔Glutathione peroxidase (GPx) 
↔Catalase  
↔Antioxidant compounds (copper, zinc, ceruloplasmin, iron, ferritin, transferrin, uric acid, 
albumin, bilirubin) 
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ed and 
participa
nts 
recomme
nded to 
avoid an 
excess of 
calories 
and/or 
lipids 
VOHF Cohort          
Farras et al. 2015,  
Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
n=33 
hypercholest
erolemic 
adults (19 
men, 14 
women) 
Age (range):  
35 to 80 
years 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
Difference in end intervention measures between groups (controlled for baseline values) 
 
Classic CVD markers  
↔ HDL composition (total-C, triglycerides, Apo-A1, Apo-AII, free cholesterol, esterified-
cholesterol, phospholipids, free cholesterol/total-C, esterified cholesterol/total-C, 
phospholipids/free cholesterol, esterified cholesterol/free cholesterol) 
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trial Attrition: 
n=3 
discontinued 
trial 
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
on 
("commo
n" olive 
oil) 
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nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
Pedret et al. 2015, Spain. 
Study period: April 2012 to September 
2012  
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=33 
hypercholest
erolemic 
adults (19 
men, 14 
women),  
Age (range):  
35 to 80 
years 
Attrition: 
n=3 
discontinued 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
Additional outcomes 
All interventions upregulated proteins related to cholesterol homeostasis, protection against 
oxidation and blood coagulation, while down-regulating proteins related to in acute-phase 
response, lipid transport, and immune response. 
HPOO had a stronger effect on the following proteins: PON-3 and PPBP which were up-
regulated. 
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trial polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
oil) 
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consump
tion 
polyphen
ol-rich 
food. 
Fernandez-Castillejo et al. 2016, Spain.  
Study period: April 2012 to September 
2012  
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=33 
hypercholest
erolemic 
adults  (19 
men, 14 
women) 
Age (range):  
35 to 80 
years 
Attrition: 
n=3 
discontinued 
trial 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
Difference in change between groups 
 
Classic CVD markers  
↓LDL-C 
↔ApoB100 
NMR LDL particle concentration (↓total, ↓IDL, ↔large, ↔small)  
 
↔HDL-C  
↔ApoA1 
NMR HDL particle concentration (↓total, ↑large, ↔medium, ↓small) and ↑size  
 
↔Triglycerides  
↔VLDL Triglycerides  
NMR VLDL particle concentration (↔total, ↔large, ↓medium, ↔small) and ↓size  
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HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
↓ApoB100 containing lipoproteins 
 
↓LDL particles /HDL particles   
↓HDL-C/HDL particles  
↓small HDL/ large HDL 
↓Lipoprotein insulin resistance index  
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ol rich 
food. 
Martin-Pelaez et al. 2016, Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
n=10 
hypercholest
erolemic 
adults (5 
men, 5 
women) 
Age (range):  
35 to 80 
years 
Attrition: not 
reported  
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
3-week 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
Difference in change between groups  
 
Classic CVD markers  
↔Weight/BMI  
↔Waist circumference  
↑Glucose  
↔SBP 
↔DBP 
 
Oxidative status 
↔ Oxidized LDL-C 
 
Inflammatory markers 
↑CRP 
↔Fecal TNF-α 
↔Fecal calprotectin 
 
Additional markers 
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reported) 
Method: 
all raw 
oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
↑Total fecal bacteria  
↔Ratio Firmicutes/Bacteroidetes 
↔Fecal IgA coated bacteria  
↔Fecal IgA 
Fernandez-Castillejo et al. 2017, Spain. Double- n=33 Dose: 25 3-week Difference in change between groups 
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Study period: April 2012 to September 
2012 
blind, 
random
ized, 
controll
ed, 
crossov
er 
clinical 
trial 
hypercholest
erolemic 
adults (19 
men, 14 
women) 
Age (range):  
35 to 80 
years 
Attrition: not 
reported  
mL/day 
Arms: 
1. HPOO; 
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
interventi
on period, 
2-week 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
 
Oxidative status 
↑ PON-3 protein  
↔PON-1 protein  
Lactonase activity (↓ raw, ↔ specific) 
Paraoxonase activity (less ↑ raw, ↔ specific)    
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oils 
replaced 
with 
olive oil, 
consume
d with 
meals. 
Participa
nts 
advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
Martin-Pelaez et al. 2017,  
Spain. 
Study period: April 2012 to September 
2012 
Double-
blind, 
random
ized, 
n=12 
hypercholest
erolemic 
adults  (7 
Dose: 25 
mL/day 
Arms: 
1. HPOO; 
3-week 
interventi
on period, 
2-week 
Difference in change between groups  
 
Classic CVD markers  
↔Total-C  
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controll
ed, 
crossov
er 
clinical 
trial 
men, 5 
women)  
Age (range):  
46 to 67 
years 
Attrition: not 
reported  
enriched 
with 
500mg/k
g 
polyphen
ols, 
2. LPOO; 
80 mg/kg 
polyphen
ols,  
3. 
HPOO+th
yme 
(data not 
reported) 
Method: 
all raw 
oils 
replaced 
with 
washout 
periods 
before 
each 
interventi
on 
("commo
n" olive 
oil) 
 
Oxidative status 
↔ Oxidized LDL-C 
 
Additional markers 
↔ Bacterial Enumerations 
↔ Short chain fatty acids  
↔ Neutral sterols 
 ↔Bile acids  
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olive oil, 
consume
d with 
meals. 
Advised 
to limit 
consump
tion 
polyphen
ol-rich 
food. 
EUROLIVE Cohort     
Covas et al. 2006. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
n=200 
healthy men 
Age (range):  
20 to 60 
years 
Attrition: 
n=18 
dropout 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
Difference in change between groups 
 
Oxidative status 
↓Conjugated dienes
b,c
  
↓Hydroxy fatty acids
c
 
↓Oxidized LDL-C
c
  
↔F2α-isoprostanes 
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controll
ed trial 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts asked 
to avoid 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
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high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Machowetz et al. 2007. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
Multice
ntre, 
double-
blind, 
n=200 
healthy men 
Age(range):  
20 to 60 
Dose: 25 
mL  
Arms: 
1. LPOO; 
3-week 
interventi
ons, 2-
week 
Difference in change between groups  
 
Oxidative status 
↔Markers of DNA /RNA oxidative damage (urinary excretion rates of guanine, guanosine, and 
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2003  random
ized, 
crossov
er, 
controll
ed trial 
years 
Attrition: 
n=18 
dropout 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
deoxyguanosine and their corresponding oxidation products) 
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ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
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and 
beer). 
Machowetz et al. 2008. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Single 
centre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=38 healthy 
men 
Age(mean±st
d): 36±2 
years 
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
Difference in change between groups  
 
Classic CVD markers  
↔BMI   
 
Inflammatory markers 
↓resistin
LPOO
  
 
 
 
 
 
 
 
126 
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
de la Torre-Carbot et al. 2010.  
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
nter, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=36 
nonsmoking 
males 
Age (range):  
20 to 60 
years 
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
Difference in change between baseline and treatment values (change between groups not 
reported) 
 
Oxidative status 
↓plasma oxLDL 
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ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
consumpt
ion) 
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legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Castaner et al. 2011. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
crossov
er, 
controll
ed trial 
n=200 
healthy men 
Age(range):  
20 to 60 
years 
Attrition: 
n=18 
dropout 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
polyphen
ols 
2. 
MPOO; 
164 
mg/kg 
3-week 
interventi
ons, 2-
week 
washout 
periods 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
Difference changes between each arm of the study (dose dependent increase related to 
polyphenol content of olive oil): 
 
Oxidative status 
↑ OLAB 
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polyphen
ols  
3. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
consumpt
ion) 
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high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Castaner et al. 2012. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
n=18 healthy 
men 
Age(mean±st
d): 38±12 
Attrition: not 
reported 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
3-week 
interventi
ons, 2-
week 
washout 
periods 
Difference in change between groups  
 
Inflammatory markers 
↓MCP1 
 
Difference changes between baseline and treatment values: 
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crossov
er, 
controll
ed trial 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
 
Additional markers 
↓Atherosclerosis-related gene expression (CD40L, IL23A, IL7R, IL8RA, and OLR1 genes) 
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high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Hernaez et al. 2014. 
5 European Countries (Spain, 
Denmark, Finland, Italy, Germany) 
Study period: September 2002 to June 
2003 
Multice
ntre, 
double-
blind, 
random
ized, 
n=47 healthy 
men  
Age 
(mean±std): 
30±9 years   
Attrition: not 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
3-week 
interventi
ons, 2-
week 
washout 
periods 
Difference in change between groups  
  
Classic CVD markers  
↔Phospholipids 
↔Apolipoprotein A1 and A2  
 
 
 
 
 
 
 
 
134 
crossov
er, 
controll
ed trial 
reported polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
↑ HDL cholesterol efflux capacity 
↑large HDL2 particles 
↔HDL particle count 
↔Triglycerides in HDL core 
↔HDL fluidity 
 
 
 
 
 
 
 
135 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
Hernaez et al. 2015. 
3 Cities (Potsdam, Germany; Kupio 
Finland, Barcelona, Spain) 
Multice
ntre, 
double-
blind, 
random
ized, 
n=25 Healthy 
men (lipid-
related 
outcomes) 
Age 
(mean±std): 
Dose: 25 
mL  
Arms: 
1. LPOO; 
2.7 
mg/kg 
3-week 
interventi
ons, 2-
week 
washout 
periods 
Difference in change between groups  
 
Classic CVD markers  
↓Apolipoprotein B-100  
↓Total LDL particles  
↓Small LDL particles  
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crossov
er, 
controll
ed trial 
32±11 years 
n=18 Healthy 
men (gene 
expression 
outcomes) 
Age 
(mean±std): 
37±12 years 
Attrition: not 
reported 
polyphen
ols 
2. HPOO, 
366 
mg/kg 
polyphen
ols 
Method: 
Replace 
all raw 
fats with 
intervent
ion oil. 
Participa
nts were 
also 
asked to 
avoid 
high 
intake of 
before 
each 
interventi
on (avoid 
olive and 
olive oil 
consumpt
ion) 
↔Large LDL particles 
↔Lipoprotein Lipase gene expression 
 
Oxidative status 
↔LDL oxidation lag time  
↔LDL oxidation rate 
 
 
 
 
 
 
 
137 
high-
antioxida
nt foods 
(e.g. 
vegetabl
es, 
legumes, 
fruits, 
tea, 
coffee, 
chocolat
e, wine, 
and 
beer). 
 
 
 
*Results represented by ↓ = significantly decreased more or lower ↑ = significantly increased more or higher or ↔ = no significant difference in change or measures. Where there are more 
than 2 groups, which groups had the significant differences is indicated by: 
a
between HPOO and LPOO, 
b
between MPOO and LPOO, and 
c
between HPOO and MPOO.  
β 
Outcomes for studies that used subsamples of a larger cohort were not extracted if another paper included a larger sample.  
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Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CD40L, CD40 Ligand; CHD, Coronary Heart Disease; CRP, C-reactive Protein; CVD, Cardiovascular Disease; HDL, High Density 
Lipoprotein; HPOO, High polyphenol Olive Oil; IL23A, Interleukin-23 alpha; IL7R, Interleukin-7 receptor; IL8RA, Interleukin 8 receptor alpha; IgA, Immunoglobulin A; LPOO, Low Polyphenol 
Olive Oil; LDL, Low Density Lipoprotein; MCP1, Monocyte chemotactic protein 1; MPOO, Medium Polyphenol Olive Oil; NMR, Nuclear magnetic resonance; OLAB, oxidized low density 
lipoprotein autoantibodies; oxLDL, Oxidized Low Density Lipoprotein; OLR1, Oxidized low-density lipoprotein receptor 1; sICAM-1, PPBP, platelet basic protein; Soluble Intercellular Adhesion 
Molecule-1; sVCAM-1, Soluble Vascular Adhesion Molecule-1; Total-C, Total cholesterol; TNF-α, Tumour Necrosis Factor Alpha 
 
 
 
 
 
 
 
 
